» Articles » PMID: 26005776

Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-coronary Artery Bypass Graft Patients: A Double-blind, Placebo-controlled, Randomized Trial

Overview
Journal J Affect Disord
Date 2015 May 26
PMID 26005776
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A decreased risk of developing depression has been reported among statin users. Aside from their lipid-lowering effects, statins are considered immunomodulatory agents and have protective effects against oxidative stress and inflammation which are well known for their association with depression. The aim of the present study was to compare the probable antidepressant effects of simvastatin and atorvastatin among post-coronary artery bypass graft (CABG) surgery patients with high and low potentials for blood-brain-barrier penetration, respectively.

Method: Forty-six outpatients who had undergone CABG in the last 6 months and suffered from mild to moderate depression participated in a parallel, double-blind, placebo-controlled trial, and were randomized to undergo 6 weeks of treatment with either simvastatin (20mg/day) or atorvastatin (20mg/day). Participants were evaluated using Hamilton depression rating scale (HDRS) at baseline and weeks 3 and 6. The primary outcome was to evaluate the efficacy of simvastatin in improving the depressive symptoms.

Result: General linear model repeated measures demonstrated significant effect for time×treatment interaction on the HDRS scores [F (1.62, 71.06)=3.41, P=0.048]. There was no significant difference between the treatment groups regarding the adverse events. No one experienced serious adverse event.

Limitation: The limitations of the present study were its small sample size and the short-term follow-up period.

Conclusion: Treatment with simvastatin seems to be well tolerated with superior antidepressant effects compared to atorvastatin in post-CABG patients. Long-term outcomes of this practice and its probable influence on other psychological aspects are yet to be investigated in future studies.

Trial Registration: Iranian registry of clinical trials (http://www.irct.ir): IRCT201410271556N68.

Citing Articles

Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis.

Xiao X, Deng H, Li P, Sun J, Tian J Front Psychiatry. 2023; 14:1203444.

PMID: 38034928 PMC: 10684957. DOI: 10.3389/fpsyt.2023.1203444.


The pathophysiology and management of depression in cardiac surgery patients.

Vu T, Smith J Front Psychiatry. 2023; 14:1195028.

PMID: 37928924 PMC: 10623009. DOI: 10.3389/fpsyt.2023.1195028.


Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder.

Su W, Hu T, Jiang C Curr Neuropharmacol. 2023; 22(5):810-842.

PMID: 37559243 PMC: 10845090. DOI: 10.2174/1570159X21666230809112028.


An online experimental medicine trial on the effect of 28-day simvastatin administration on emotional processing, reward learning, working memory and salivary cortisol in healthy volunteers at risk for depression: OxSTEP protocol.

Waters S, De Giorgi R, Quinton A, Gillespie A, Murphy S, Cowen P BJPsych Open. 2023; 9(4):e110.

PMID: 37313755 PMC: 10304861. DOI: 10.1192/bjo.2023.44.


Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories.

Hassamal S Front Psychiatry. 2023; 14:1130989.

PMID: 37252156 PMC: 10213648. DOI: 10.3389/fpsyt.2023.1130989.